Cansino Biologics

China‑based CanSino Biologics develops and manufactures a diversified vaccine portfolio, including the COVID‑19 Convidecia®, Ebola Ad5‑EBOV, meningococcal MCV2/4, and multiple Phase I pneumococcal and pertussis candidates, positioning it as a key player in global vaccine supply.

Headquarters: China (CHN)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 1,105
HQ: Tianjin

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
688185	Cansino Biologics Cap: 17.1B	EQUITY	SHH	CNY	CNE100004BM0	Active	📈